{"id":"W2052054991","doi":"10.1182/blood-2012-02-410688","title":"A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Canadian Cancer Society Research Institute; Ariad Pharmaceuticals; National Cancer Institute; National Institutes of Health; Pfizer; Oregon Health and Science University; Bristol-Myers Squibb","keywords":"Dasatinib; Medicine; Nilotinib; Imatinib; Internal medicine; Myeloid leukemia; Imatinib mesylate; Gastroenterology; Randomized controlled trial; Tyrosine-kinase inhibitor; Immunology; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001436961,0.0006087847,0.002236428,0.0003614645,0.00008010469,0.00002358639,0.0003122594,0.0003935044,0.001246835],"category_scores_gemma":[0.001703846,0.0005222813,0.0006187774,0.0005724076,0.0003250446,0.000287436,0.0001437536,0.000587173,0.0002135838],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003880346,"about_ca_system_score_gemma":0.004057211,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009030135,"about_ca_topic_score_gemma":0.0002174415,"domain_scores_codex":[0.9954041,0.0004541902,0.001559097,0.0006043655,0.0007913418,0.001186875],"domain_scores_gemma":[0.9959253,0.001741481,0.0006449625,0.001127976,0.0000971738,0.0004630778],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9590154,0.007804067,0.0006986758,0.0005848236,0.001621331,0.000238727,0.001765139,0.00002921955,0.0114558,0.0002918354,0.0006282524,0.01586678],"study_design_scores_gemma":[0.9748926,0.003504396,0.0004699435,0.0004782845,0.001789529,0.0000541681,0.00009312493,0.0005897876,0.01606111,0.00002186749,0.001635789,0.0004093538],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807906,0.006998977,0.00003035962,0.0001548778,0.001051294,0.00490052,0.00005332928,0.0001397576,0.005880256],"genre_scores_gemma":[0.9939719,0.0009143878,0.001183785,0.0000615697,0.002115814,0.0009377434,0.0002541439,0.0001111439,0.000449514],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01587729,"threshold_uncertainty_score":0.9999436,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02894547002878551,"score_gpt":0.3226977424825182,"score_spread":0.2937522724537327,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}